BGBC016 STK11 NSCLC (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug called bemcentinib (the study drug) is a safe and effective option when it is combined with the standard therapy for non-small cell lung cancer (1 immunotherapy drug and 2 chemotherapy drugs).

What is the Condition Being Studied?

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with advanced non-squamous non-small cell lung cancer.

For more information about who can be in this study, please contact the study team at annmarie.peters@duke.edu.

Age Group
Adults

What is Involved?

If you join this study, you will go through a screening period to make sure you are eligible. During the screening period you will:

  • Have blood draws
  • Have imaging scans (CT and MRI)
  • Have 2 procedures to check your heart function, an electrocardiogram (ECG) and either an echocardiogram (ECHO) or a multigated acquisition scan (MUGA)

If you are eligible to get the study drug, you will:

  • Take the study drug by month once per day
  • Received the standard therapy (1 immunotherapy drug and 2 chemotherapy drugs) every 21 days by injection into a vein (IV)
  • Study Details

    Full Title
    Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation. (BGBC016 STK11 NSCLC)
    Principal Investigator
    Medical Oncologist
    Protocol Number
    IRB: PRO00112972
    NCT: NCT05469178
    Phase
    Phase I/II
    ClinicalTrials.gov
    Enrollment Status
    Open for Enrollment